VTP-27999 is primarily investigated for its potential therapeutic applications in treating hypertension and related cardiovascular conditions. It functions as an inhibitor of renin, a key enzyme in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance. By blocking renin activity, it helps reduce the production of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. This mechanism makes it a promising candidate for managing high blood pressure, particularly in patients who may not respond adequately to other antihypertensive therapies. Additionally, its role in modulating the RAAS pathway suggests potential benefits in addressing heart failure and kidney diseases associated with hypertension. Research continues to explore its efficacy, safety, and potential broader clinical applications.